4,400 Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 23.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,070 shares of the specialty pharmaceutical company’s stock after buying an additional 4,400 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Jazz Pharmaceuticals were worth $5,341,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in JAZZ. USA Financial Formulas acquired a new stake in shares of Jazz Pharmaceuticals during the 1st quarter valued at approximately $25,000. Pension & Wealth Management Advisors Inc. acquired a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $32,000. Ameritas Advisory Services LLC purchased a new position in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $47,000. Westpac Banking Corp purchased a new position in Jazz Pharmaceuticals in the 1st quarter valued at approximately $51,000. Finally, Root Financial Partners LLC increased its stake in Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after purchasing an additional 89 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the completion of the sale, the executive vice president owned 65,686 shares in the company, valued at approximately $16,401,794.20. This trade represents a 53.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Cozadd sold 6,000 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the completion of the transaction, the director directly owned 345,875 shares of the company’s stock, valued at $79,665,388.75. The trade was a 1.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 94,121 shares of company stock worth $23,337,922 in the last ninety days. 4.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have commented on the company. Wells Fargo & Company boosted their target price on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Robert W. Baird lifted their price target on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Piper Sandler boosted their price objective on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a report on Thursday, September 24th. They set a “buy” rating and a $337.00 target price for the company. Finally, UBS Group lifted their target price on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a research report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $292.05.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $215.98 on Monday. The business’s fifty day moving average price is $231.96 and its two-hundred day moving average price is $216.24. The stock has a market cap of $14.02 billion, a PE ratio of 14.90, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. Jazz Pharmaceuticals PLC has a one year low of $128.80 and a one year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same period last year, the firm earned ($8.25) earnings per share. The business’s revenue was up 15.5% compared to the same quarter last year. On average, analysts forecast that Jazz Pharmaceuticals PLC will post 10.87 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.